98%
921
2 minutes
20
Introduction: Concomitant cardiovascular comorbidities in patients with cancer are not uncommon. There is limited data on the impact of cardiovascular comorbidities on in-hospital mortality in patients admitted with neutropenic fever.
Methods: This is a retrospective cohort study using the 2016 NIS database of adults (> 18 years old) hospitalized for neutropenic fever as the primary diagnosis. The primary outcome studied is all-cause mortality in patients with neutropenic fever. ICD-10-CM codes were used to identify cardiovascular risk factors including smoking; hyperlipidemia; peripheral vascular diseases; hypertension; history of cerebrovascular disease or transient ischemic attack; and cardiovascular morbidities including atrial fibrillation, coronary artery disease, and congestive heart failure. Multivariate linear regression analysis was used to adjust for cofounders.
Results: A total of 28,060 patients were admitted with neutropenic fever in 2016. Average age was 43.9 ± 1.7 years, and 49.3% were females. Among the cases identified, 205 patients died during hospitalization with an overall in-hospital mortality of 0.7%. Atrial fibrillation was independently associated with higher in-hospital mortality (odds ratio [OR] 3.01; CI 1.38 to 6.57; p = 0.005) as was congestive heart failure (OR 3.15; CI 1.08 to 10.14; p = 0.049).
Conclusion: Atrial fibrillation and congestive heart failure were associated with higher inpatient mortality in patients with neutropenic fever. Identifying the risk factors for increased mortality in patients with neutropenic fever is important for risk stratification and guiding clinicians in taking therapeutic decisions in this set of patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00520-020-05518-6 | DOI Listing |
Klin Mikrobiol Infekc Lek
June 2025
Clinic of Infectious Diseases, Central Military Hospital, Prague, Czech Republic, e-mail:
Objective: To evaluate the quality of care provided to patients with febrile neutropenia (FN) hospitalized at the Depart-ment of Infectious Diseases, Military University Hospital Prague, as a foundation for improving the management of this condition.
Material And Methods: A retrospective observational analysis of patients diagnosed with the ICD-10 code D70 from 1 January 2015 to 1 June 2023. All evaluated parameters were selected primarily to facilitate the assessment of care quality and compliance with recommended practices.
J Pediatr Surg
September 2025
Division of Pediatric General and Thoracic Surgery. Cincinnati Children's Hospital Medical Center. 3333 Burnet Avenue, Cincinnati, Ohio 45229; Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address:
Background: Postoperative fever is common following cancer resection and often prompts extensive, costly workups. The purpose of this study was to determine the incidence of and risk factors for postoperative fever in oncology patients, evaluate incidence of true infection, and determine the utility of fever workup.
Methods: Single institution retrospective chart review (2018-2023) identified postoperative oncology patients who developed postoperative fever (≥38.
Am J Emerg Med
August 2025
Department of Emergency Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States of America. Electronic address:
Background: Chemotherapy-associated febrile neutropenia (FN) is a common, life-threatening oncologic emergency. Scores to identify low-risk patients eligible for outpatient treatment, like the Multinational Association for Supportive Care in Cancer (MASCC), Clinical Index of Stable Febrile Neutropenia (CISNE), and quick Sepsis Related Organ Failure Assessment (qSOFA) scores, are infrequently used. New tools are needed to inform risk and enable appropriate management.
View Article and Find Full Text PDFInvest New Drugs
September 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
As monotherapy, PARP inhibitors have little cytotoxic effect in tumors without homologous recombinant repair (HRR) alterations. Supported by preclinical models, we hypothesized that the PARP inhibitor talazoparib in combination with temozolomide chemotherapy could induce DNA damage leading to cell death and tumor response in patients with metastatic castration-resistant prostate cancer (mCRPC) without HRR alterations. In this phase 1b/2 trial (NCT04019327; registration date July 11, 2019), patients with progressive mCRPC without HRR mutations who failed at least one androgen receptor signaling inhibitor were enrolled in escalating doses of intermittent talazoparib plus temozolomide to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) in Phase 1b.
View Article and Find Full Text PDFAsian Biomed (Res Rev News)
August 2025
Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand.
Background: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in diffuse large B-cell lymphoma (DLBCL) patients undergoing rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone every 21 d (R-CHOP-21) chemotherapy varies based on physician discretion.
Objectives: The present study aims to investigate the impact of primary G-CSF prophylaxis on febrile neutropenia (FN) and other outcomes in DLBCL patients receiving R-CHOP-21 in real-world practice.
Methods: Medical records of 103 newly diagnosed DLBCL patients, aged 18-80 years, were retrospectively analyzed.